NSCLC (Issue 10)
Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
January 18th 2016Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients
January 18th 2016Marianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.
Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLC
January 14th 2016A team from the Scripps Research Institute and Bristol-Myers Squibb recently collaborated to collectively develop a method for complete chemical synthesis of antroquinonol and to test the biologic activity of the chemically synthesized product. Contrary to previous reports, the study reported minimal in vitro and in vivo antitumor activity of chemically synthesized antroquinonol A.
Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLC
January 13th 2016The success of the immunotherapies pembrolizumab and nivolumab for the treatment of non-small cell lung cancer (NSCLC), and the promising results in NSCLC for the investigational agent atezolizumab, have generated an interest in new combinations with other agents
Lung Cancer Research Shows Distinct Genomic Differences in Younger Patients
January 8th 2016A recent study demonstrated that specimens from patients with lung cancer under the age of 50 years appear to be enriched with molecular alterations that are amenable to targeted treatment.
Lung Cancer Incidence and Mortality Review Shows No Ethnic Differences in Women
January 7th 2016There are no differences in lung cancer incidence or mortality among women of different ethnic groups when adjusted for age, smoking, and other factors, according to an article recently published in the Journal of Clinical Oncology.
NSCLC Study Shows Surprising Association Between Reduced Endocytic Activity and Metastases
December 31st 2015Non-small cell lung cancer with mutations in the KRAS gene may be associated with reduced activity of a key endocytic pathway and a mesenchymal phenotype, which may cause metastases.
